Saturday, April 27th, 2024

Breaking News

‘You have to stay tuned’: Trump spokeswoman hints former president will soon address COVID vax fallout, will ‘investigate Big Pharma’

‘You have to stay tuned’: Trump spokeswoman hints former president will soon address COVID vax fallout, will ‘investigate Big Pharma’

(Natural News) A spokeswoman for former President Donald Trump, who is leading in most polls to become the 2024 GOP nominee, suggested during a recent interview with Natural News founder and editor Mike Adams, The Health Ranger, that he is preparing to address various issues supporters still have with him regarding his “Operation Warp Speed” development of harmful COVID vaccines.

After Adams explained that many of Trump’s supporters wonder why he hasn’t addressed “what we know now about those vaccines,” Liz Harrington, the spokeswoman, responded: “Well, I think you have to stay tuned.”

“I think potentially in the future he might, but I do also think there are a lot of people, right or wrong, that wanted this vaccine,” she said, noting that, at the time — 2020, in the midst of a pandemic that most people still knew very little about — tens of millions of Americans were frightened and pressing the administration to respond to it more quickly.

“What President Trump did was gave people kind of a choice. You know, he can’t make that choice for you,” Harrington continued. “We’re gonna have to do investigations — he just put out a policy video on chronic illnesses for children, affecting children. Nobody’s talking about this.”

take our poll - story continues below
[gravityforms id="56"]
Completing this poll grants you access to DC Dirty Laundry updates free of charge. You may opt out at anytime. You also agree to this site's Privacy Policy and Terms of Use.

“What President Trump is saying is we cannot allow Big Pharma to be making profits over kids being sick,” she added. “We need to investigate. So I think investigations like that will be happening for a lot of things with Big Pharma.”

Adams noted that Democratic presidential contender Robert F. Kennedy told him during a previous interview that he would support criminal investigations into Big Pharma CEOs and companies to see if they were pushing vaccines and medications they knew were not fully tested or harmful. He then asked Harrington if Trump would, as well.

“I think so,” she said. “He’s already called for investigations related to Big Pharma. On this specific question, I’ll definitely have to ask him and get back to you, but I think he would definitely support that.


“I mean, the more sunlight you have, it’s always a good thing,” she added, alluding to transparency. “President Trump always supports that.”

She went on to say that Trump would likely also support getting to the bottom of how the pandemic was politically weaponized to steal his reelection.

“The same thing throughout all of these things is accountability,” Harrington said. “You can’t fix the deep state, you can’t fix the corruption with corporations and the endless wars and the defense lobby and everything else unless you really get truth and accountability.”

Operation Warp Speed (OWS) was a public-private partnership initiated by the Trump administration in May 2020, aimed at accelerating the development and distribution of COVID-19 vaccines, therapeutics, and diagnostics.

One of the primary goals of the OWS was to develop a safe and effective vaccine at breakneck speed. From the instant the coronavirus invaded our shores, the Trump administration raced into action in an attempt to develop a safe and effective vaccine.

The OWS aimed to deliver 300 million doses of COVID-19 vaccines by January 2021. By the end of December 2020, over 11 million doses of the Pfizer-BioNTech and Moderna vaccines were administered to Americans, exceeding OWS’s initial target of 10 million doses by the end of the year. The Trump administration also invoked the Defense Production Act to prioritize domestic vaccine manufacturing and distribution and provided funding to vaccine companies for large-scale manufacturing and clinical trials.

The OWS faced several challenges during its implementation. Manufacturing challenges, including limited manufacturing capacity and disruptions to supply chains, have impacted vaccine production. DOD and HHS officials worked with vaccine companies to mitigate these challenges. The OWS also faced criticism for its lack of transparency and uneven distribution of vaccines.

Some experts argued that the OWS prioritized speed over safety and that the vaccines were authorized for emergency use without adequate data on their long-term safety and efficacy.

WATCH:

Sources include:

Brighteon.com

USMCU.edu

GAO.gov

(Visited 554 times, 1 visits today)

Your Daily Briefing:

Fight Online Censorship!

Get the news Google and Facebook don't want you to see: Sign up for DC Dirty Laundry's daily briefing and do your own thinking!


Translate »